非清髓性单倍体相合外周血干细胞移植后伊沙佐米的前瞻性2期试验
这项2期研究在非清髓性单倍体相合移植后以伊沙佐米替代吗替麦考酚酯进行移植物抗宿主病预防,联合移植后环磷酰胺和他克莫司。25例患者中位随访33.5个月,1年复发/进展累积发生率为24%、3年为44%,未达到预设的降低1年复发风险目标;3年非复发死亡率为12%,3-4级急性GVHD为8%,中重度慢性GVHD为19%,1年总生存率为84%、3年为74%。
要点
- 伊沙佐米替代吗替麦考酚酯后植入可靠,无继发性植入失败。
- 1年复发/进展累积发生率为24%,未达到预设的降低1年复发风险目标。
- 3年非复发死亡率为12%,1年总生存率为84%、3年为74%。
核心结论
- 在单倍体相合移植后以伊沙佐米替代吗替麦考酚酯,可获得可靠植入、临床显著GVHD发生率相当、复发和非复发死亡率相当以及有利的总生存。
研究设计与样本
- 前瞻性2期试验,纳入25例接受非清髓性单倍体相合外周血干细胞移植的患者,中位年龄62岁(范围35-77岁)。
- 伊沙佐米从第+5天开始,每28天周期第1、8、15天口服4 mg,最多12个周期,后续周期允许因毒性减量。
- GVHD预防联合移植后环磷酰胺和他克西莫司。
主要发现
- 中位随访33.5个月,1年复发/进展累积发生率为24%,3年为44%,未达到预设的降低1年复发风险目标。
- 全部患者均植入,无继发性植入失败,3年非复发死亡率为12%。
- 3-4级急性GVHD累积发生率为8%,中重度慢性GVHD发生率为19%。
- 19例患者存活,估计1年总生存率为84%,3年总生存率为74%。
- 血液学和皮肤毒性常见但可控。
局限性
- 1年复发/进展累积发生率为24%,未达到统计学预设的降低1年复发风险目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Proteasome inhibition results in extensive immunomodulatory effects that augment natural killer cell cytotoxicity and inhibit aspects of T-cell, B-cell, and dendritic cell function. We performed a phase 2 study that examined the effects of ixazomib for graft-versus-host disease (GVHD) prophylaxis (up to 12 cycles) with posttransplant cyclophosphamide and tacrolimus after standard nonmyeloablative haploidentical donor transplantation (HIDT). Ixazomib was started on day +5 (4 mg on days 1, 8, and 15 of a 28-day cycle), with dose reductions allowed in future cycles for toxicity. All patients received peripheral blood stem cells. Twenty-five patients were enrolled with a median age of 62 years (range, 35-77 years) who had acute leukemia (4), myelodysplastic syndrome (7), non-Hodgkin lymphoma/Hodgkin lymphoma/chronic lymphocytic leukemia (8), and myeloma (6). The hematopoietic cell transplant comorbidity index was ≥3 in 68% of the patients. After a median follow-up of 33.5 months, the cumulative incidence of relapse/progression at 1 year was 24% and 44% at 3 years, which failed to meet the statistically predefined goal of decreasing 1-year risk of relapse. Engraftment occurred in all patients with no secondary graft failure, and 3-year nonrelapse mortality (NRM) was 12%. Cumulative incidence of grade 3 to 4 acute GVHD was 8%, whereas moderate-to-severe chronic GVHD occurred in 19%. Nineteen patients survive with an estimated 1-year overall survival (OS) of 84% and 3-year OS of 74%. Hematologic and cutaneous toxicities were common but manageable. The substitution of ixazomib for mycophenolate mofetil (MMF) post-HIDT results in reliable engraftment, comparable rates of clinically significant GVHD, relapse and NRM, and favorable OS. This trial was registered at www.clinicaltrials.gov as # NCT02169791.
引用
- Solomon SR, Solh M, Zhang X, et al. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant. Blood Adv. 2020. PMID: 32777064. doi:10.1182/bloodadvances.2020001958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。